ISPAD Clinical Practice Consensus Guidelines 2022: Editorial.
ISPAD Clinical Practice Consensus Guidelines 2022: Editorial.
复制标题
DOI：
10.1111/pedi.13441
复制
发表时间：
2022-12
影响因子：
3.4
通讯作者：
Wolfsdorf, Joseph I.
中科院分区：
文献类型：
--
作者：
Craig, Maria E.;Codner, Ethel;Mahmud, Farid H.;Marcovecchio, M. Loredana;DiMeglio, Linda A.;Priyambada, Leena;Wolfsdorf, Joseph I.
关键词：
The ISPAD 2022 clinical practice consensus guidelines were developed and completed during unprecedented times. First, due to the impact of the COVID-19 pandemic on people with diabetes and their families, diabetes professionals and care teams, our own families, health systems throughout the world, public health policy, and our individual work practices. Second, in the 4years since the 2018 guidelines, 1 we have also experienced considerable evolution of technology for glucose monitoring, insulin delivery, and health care delivery. Moreover, in the 27years since the first guidelines were published, 2 overall knowledge has profoundly impacted the management of diabetes, particularly in young children and youth, including wider use of insulin analogs, insulin pumps, continuous glucose monitoring (CGM), and automated insulin delivery devices. In recognition of these advances in diabetes care, the 2018 single guideline on diabetes technologies has been split into two separate guidelines for2022: glucose monitoring and insulin delivery. The guideline on glycemic targets highlights the role of technology, with adoption of a unified fingerstick blood glucose level (BGL) target of between 4 and 10 mmol/L (70–180 mg/dl), which aligns with the target CGM time in range, along with a tighter fasting target range of 4–8 mmol/L (70–144 mg/dl).Technological advances have also impacted prediction and prevention of T1D. While individuals with a first-degree relative with T1D have 15-fold increased risk of T1D, approximately 85% of those with a new diagnosis do not have a family history of T1D. Hence, general population screening programs to determine T1D risk are expanding, and collaborative T1D networks testing interventions seeking to delay the disease process at all stages of disease are growing, including the use of CGM as a way to assess risk and track glycemia in these settings. 3
登录
查看更多内容
影响因子：
3.4
作者：
Priyambada, Leena;Wolfsdorf, Joseph, I;Craig, Maria E.
通讯作者：
Craig, Maria E.
影响因子：
3.5
作者：
Cooper, A.;Kanumilli, N.;Wilmot, E.
通讯作者：
Wilmot, E.
影响因子：
44.5
作者：
Gregory, Gabriel A.;Robinson, Thomas I. G.;Ogle, Graham D.
通讯作者：
Ogle, Graham D.
影响因子：
3.4
作者：
Besser, Rachel E. J.;Bell, Kirstine J.;Haller, Michael J.
通讯作者：
Haller, Michael J.